KRAS and neoplasm: We used the murine CRC cell line CT26, which harbors a homozygous KRAS mutation at G12D and shares with aggressive, undifferentiated, and refractory human CRC cells [19], and thus contains highly severe tumor model features for the evaluation of the effectiveness of FTD/TPI.